Table 3

SIR for cancers at all sites and at all sites except NMSC according to selected subgroup variables

	All sites					All non-NMSC sites
Group	PY	Obs	Exp	SIR (95% CI)	p Value	PY	Obs	Exp	SIR (95% CI)	p Value
By diagnosis
MPA	1040	18	15.04	1.20 (0.71–1.89)	0.51	1042	15	12.62	1.19 (0.67–1.96)	0.57
GPA	1513	32	16.67	1.92 (1.31–2.71)	0.001	1537	20	14.38	1.39 (0.85–2.15)	0.19
By sex
Men	1330	33	19.77	1.67 (1.15–2.34)	0.008	1349	23	16.94	1.36 (0.86–2.04)	0.19
Women	1223	17	11.94	1.42 (0.83–2.28)	0.20	1231	12	10.06	1.19 (0.62–2.08)	0.62
By age at entry
≤58 years	1259	11	6.4	1.73 (0.86–3.10)	0.12	1271	7	5.44	1.29 (0.52–2.65)	0.61
>58 years	1294	39	25.36	1.54 (1.09–2.10)	0.01	1309	28	21.65	1.30 (0.86–1.88)	0.21
By BVAS at entry
≤18	1314	23	16.40	1.40 (0.89–2.10)	0.14	1326	17	14.13	1.20 (0.70–1.93)	0.51
>18	1239	27	15.30	1.76 (1.16–2.57)	0.009	1254	18	12.86	1.40 (0.83–2.21)	0.20
By CKD stage at entry
≤2	823	15	6.21	2.42 (1.35–3.98)	0.004	838	10	5.52	1.81 (0.87–3.33)	0.11
>2	1730	35	25.50	1.37 (0.96–1.91)	0.09	1742	25	21.48	1.16 (0.75–1.72)	0.50
By trial
Generalised AAV	999	17	11.96	1.42 (0.83–2.28)	0.20	1020	10	10.42	0.96 (0.46–1.76)	1.00
Early systemic AAV	486	7	3.88	1.80 (0.73–3.72)	0.20	487	6	3.33	1.80 (0.66–3.92)	0.24
Severe renal AAV	508	14	8.57	1.63 (0.89–2.74)	0.11	510	10	7.09	1.41 (0.68–2.59)	0.36
Generalised, renal AAV	560	12	7.30	1.64 (0.85–2.87)	0.14	563	9	6.16	1.46 (0.67–2.77)	0.34
By follow-up duration
1–3 years	1254	23	14.88	1.55 (0.98–2.32)	0.06	1256	20	12.52	1.60 (0.98–2.47)	0.06
3–5 years	627	11	7.97	1.38 (0.69–2.47)	0.36	631	9	6.76	1.33 (0.61–2.53)	0.48
>5 years	673	16	8.85	1.81 (1.03–2.94)	0.04	692	6	7.72	0.78 (0.29–1.69)	0.70
By geographical area
IE/UK	808	22	10.79	2.04 (1.28–3.09)	0.004	817	13	9.02	1.44 (0.77–2.46)	0.25
DK/FN/LT/SE	486	8	5.26	1.52 (0.66–3.00)	0.32	490	5	5.19	0.96 (0.31–2.25)	1.00
CH/CZ/GE/NL/PL	703	8	8.08	0.99 (0.43–1.95)	1.00	715	5	6.31	0.79 (0.26–1.85)	0.79
BE/FR	158	4	2.27	1.76 (0.48–4.51)	0.39	158	4	1.95	2.05 (0.56–5.25)	0.27
IT/MX/SP	398	8	5.31	1.51 (0.65–2.97)	0.34	398	8	4.53	1.77 (0.76–3.48)	0.18

AAV, antineutrophil cytoplasm antibody-associated vasculitis; BE, Belgium; BVAS, Birmingham vasculitis activity score; CH, Switzerland; CKD, chronic kidney disease stage; CZ, Czech Republic; DK, Denmark; Exp, expected; FN, Finland; FR, France; GE, Germany; GPA, granulomatosis with polyangiitis (Wegener's); IE, Ireland; IT, Italy; LT, Lithuania; MPA, microscopic polyangiitis; MX, Mexico; NL, The Netherlands; NMSC, non-melanoma skin cancer; Obs, observed; PL, Poland; PY, person-years; SE, Sweden; SP, Spain; UK, United Kingdom.